Hikma and Fresenius best positioned from Trumps generic drug tariffs, says Citi
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trumps proposed tariffs...…
18,760€
0,16%
Echtzeit-Aktienkurs Hikma Pharmaceuticals PLC
Bid:
Ask:
Nachrichten zur Hikma Pharmaceuticals PLC Aktie
Hikma recovery story still has further to run after recent rally, says Panmure
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has already rebounded 30% from its lows but Panmure Liberum believes the generic drugmaker still offers...…
Citi starts Hikma at buy with strategy reset offering compelling entry point
Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) with a buy rating and a £17 price target, arguing…
SIGA (SIGA) Q1 2026 Earnings Call Transcript
Image source: The Motley Fool.DATEThursday, May 7, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Diem NguyenChief Financial Officer…
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
…
Hikma Pharma tumbles on softer guidance as buyback fails to soften pill
Hikma Pharmaceuticals PLC shares fell almost 16% to 1,390p after the drugs group delivered results for 2025 in line with forecasts but…
Hikma falls to three-year low as CEO steps down with immediate effect
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares fell 1.45p to 1,494p, its lowest since late 2022, on news that Riad Mishlawi is stepping…
Hikma Pharmaceuticals: Due a dose of confidence
After a rough six months in which its shares have shed a quarter of their value, Hikma Pharmaceuticals PLC (LSE:HIK,…
Hikma Pharma tumbles as injectables guidance cut
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares fell almsot 13% to 1,547p after the generic drug manufacturer lowered medium-term guidance for its...…
If Hikma can reassure with quarterly update it should be catalyst, says broker
If Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) can deliver a reassuring third-quarter trading update next week, broker Panmure Liberum it could start to...…
Hikma Pharma tumbles as first-half profits dented by shifting product mix
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) was the biggest faller on the FTSE 100 on Thursday morning after the drugmakers interim results…
Hikma Pharmaceuticals to report H1 2025 results on August 7 By Investing.com
Hikma Pharmaceuticals to report H1 2025 results on August 7…
Hikma Pharma jumps as it hikes medium-term outlook
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) saw its shares jump 8% after it put out a midday update on its outlook, seeing…
Hikma Pharmaceuticals gets ’BBB’ rating upgrade from S&P on strong momentum By Investing.com
Hikma Pharmaceuticals gets ’BBB’ rating upgrade from S&P on strong momentum…
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.…
Hikma shares fall 5% as stock succumbs to profit taking after strong results and outlook statement
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares fell five per cent in early trading as investors took profits despite the company…
Investing in Hikma Pharmaceuticals (LON:HIK) five years ago would have delivered you a 38% gain
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...…
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Pre-Recorded Presentation Transcript
…
Hikma Pharmaceuticals shares surge on upbeat guidance By Investing.com
Hikma Pharmaceuticals shares surge on upbeat guidance…
Hikma Pharmaceuticals rallies following bullish first-half earnings
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares bounced 7.6% higher on Thursday following publication of its half-year financial report. “We had…
Hikma Pharma buys Xellia assets for US$135m
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has bought a raft of US injectable or finished dosage form (FDF) assets from Copenhagen-based…
Hikma beefs up complex manufacturing skillset with Xellia assets
Hikma Pharmaceuticals has bought a raft of US injectable or finished dosage form (FDF) assets from Copenhagen-based Xellia Pharmaceuticals for US$135...…